Pharsight

Drugs that contain Canagliflozin; Metformin Hydrochloride

1. Invokamet patents expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(5 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 1 month from now)

US11576894 JANSSEN PHARMS Combination therapy for the treatment of diabetes
Jul, 2030

(6 years from now)

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

2. Invokamet Xr patents expiration

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(5 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 1 month from now)

Market Authorisation Date: 20 September, 2016

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents